UNSPSC 51322903: Pitavastatin

This classification denotes a hmg-coa reductase inhibitor with the molecular formula C25H24FNO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M5681Q5F9P, chemically known as 6-heptenoic acid, 7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl)-3,5-dihydroxy-, (s-(r*,s*-(e)))- but generally known as pitavastatin, which bears US NIH Compound Identifier 6366718. European Medicines Agency schedules Pitavastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21363.

UNSPSC 51322903 Pitavastatin, a Commodity code, covers pharmaceutical supply procurement by state and local governments, though recent solicitation activity shows broader emergency and chronic-care medication buys rather than pitavastatin-specific contracts. State and local purchasing departments, health agencies, and cooperative purchasing alliances solicit medications under this code for fire rescue services, pharmacy benefit programs, and multi-jurisdictional distribution networks. The scope of actual work includes supplying generic and branded pharmaceuticals with firm pricing, FDA compliance, current Good Manufacturing Practices certification, Drug Supply Chain Security Act compliance, minimum shelf-life guarantees, Safety Data Sheets documentation, and logistics management including delivery, expiration monitoring, and pickup of expired stock. Issuing bodies span city fire departments and state health commissions as end-users, with state procurement offices and multistate cooperative purchasing alliances as contracting entities.

Recent activity appears primarily in Florida, Texas, and Minnesota. The City of Tampa issued an IFB (Solicitation 26P00188) on April 24, 2026 for Advanced Life Support Medications—labetalol, epinephrine, adenosine, and diltiazem for Tampa Fire Rescue—with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00, offering a 5 percent Small Local Business Enterprise bid discount. The Texas Health and Human Services Commission posted a Request for Information (RFI No. HHS0017013) on April 3, 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring direct contracting models outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802) due March 26, 2026 for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (Cencora, Cardinal Health, Morris & Dickson) to participating state and local government facilities across multiple jurisdictions including Oregon, with contract effectiveness on July 1, 2026.